Grant: Master's Award: Canada Graduate Scholarships
McGill University
$17,500.00
Regulation of androgen receptor activity by ZIC2
EF 2023-24
Résumé
Prostate cancer (PCa) is the second most common form of cancer in men. A common therapy to treat PCa is to remove testosterone from the blood by castration, known as androgen deprivation therapy. This treatment is sometimes worse than leaving the cancer alone, as it can progress to castration-resistant prostate cancer, in which the tumour doesn't need the body's testosterone to grow. This type of cancer has no effective treatment and could be a more severe form of cancer than previously. A protein called ZIC2 has been shown to resist and promote tumour growth in various forms of cancer. Recently, my colleagues and I observed a loss of ZIC2 in androgen receptor-expressing prostate cancer cells upon androgen treatment. This phenomenon correlates with chromatin reprogramming at ZIC2 sites for gene sets known to suppress tumour formation. I propose that androgen-directed depletion of ZIC2 promotes changes in chromatin leading to the expression of certain genes that cause PCa progression. I will investigate the necessity of ZIC2 for PCa progression in cell lines representing known stages of PCa progression. I will identify gene programs under the direct control of ZIC2 in cells treated with or without androgen, as well as with lower or higher levels of ZIC2. I will identify factors that interact with DNA-bound ZIC2 in the nucleus. Overall, this project will provide a better understanding of the mechanisms that drive prostate cancer progression, with the aim of improving current therapies and slowing the progression of prostate cancer to a more serious outcome.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
505828
Name
Alfonso Anthony
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Regulation of androgen receptor activity by ZIC2
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Androgen Receptor; Chromatin Remodelling Complex; Prostate Cancer; Zic2
Abstract
Prostate cancer (PCa) is the second most common form of cancer in men. A common therapy to treat PCa is to remove testosterone from the blood by castration, known as androgen deprivation therapy. This treatment is sometimes worse than leaving the cancer alone, as it can progress to castration-resistant prostate cancer, in which the tumour doesn't need the body's testosterone to grow. This type of cancer has no effective treatment and could be a more severe form of cancer than previously. A protein called ZIC2 has been shown to resist and promote tumour growth in various forms of cancer. Recently, my colleagues and I observed a loss of ZIC2 in androgen receptor-expressing prostate cancer cells upon androgen treatment. This phenomenon correlates with chromatin reprogramming at ZIC2 sites for gene sets known to suppress tumour formation. I propose that androgen-directed depletion of ZIC2 promotes changes in chromatin leading to the expression of certain genes that cause PCa progression. I will investigate the necessity of ZIC2 for PCa progression in cell lines representing known stages of PCa progression. I will identify gene programs under the direct control of ZIC2 in cells treated with or without androgen, as well as with lower or higher levels of ZIC2. I will identify factors that interact with DNA-bound ZIC2 in the nucleus. Overall, this project will provide a better understanding of the mechanisms that drive prostate cancer progression, with the aim of improving current therapies and slowing the progression of prostate cancer to a more serious outcome.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Alfonso, Anthony
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~